发生过心肌梗塞而幸免未死的患者,而都还有再发的危险,所以减少其危险发作是非常必要的.1978年曾有人报道苯磺唑酮对幸免未死的心肌梗塞患者,具有益处。1979年上半年,因急性心肌梗塞在 Stracathro 医院住院的所有幸存者64例,出院后服用苯磺唑酮,每日3次,每次200mg。下半年住院者62例,出院后不用此药,以资对照.两组患者住院期间均卧床休息7～12天,以安定镇静。均接受新双香豆素或皮下注射肝素抗凝治疗,平均住院12～18天出院.64例患者用苯磺唑酮七个月或更长时间;对照组除1例因服用阿斯匹林被排除外,其余62例均未服用任何药物.所有吸烟者,住院期间停止吸烟。出院时嘱患者限制动物脂 It is necessary to reduce the risk of a heart attack in patients who have survived myocardial infarction but are still at risk of recurrent episodes. In 1978, it was reported that the use of triptorelin was beneficial to patients who had survived uninucleated myocardial infarction . In the first half of 1979, 64 survivors were hospitalized at Stracathro Hospital for acute myocardial infarction. After discharge, they were given tribenzidone three times a day for 200 mg each. In the second half of 62 hospitalized patients, after discharge from the drug, to control .Two groups of patients were hospitalized during bed rest for 7 to 12 days, to calm and calm. All received neocoumarin or subcutaneous heparin anticoagulation therapy, the average hospital discharge 12 to 18 days were discharged in 64 patients with tribenurone 7 months or longer; control group except for 1 case due to taking aspirin Were excluded, the remaining 62 patients did not take any drugs.All smokers, stop smoking during hospitalization. Patients were asked to limit the release of tallow